No evidence of malignancy was identified in either study [17,44], consistent with JAK3 GOF mutations being able to cause a mild lymphoproliferative disorder rather than overt leukemia, which requires additional genetic events. This evidence concerns the gene JAK3 and lymphoproliferative syndrome.